Trial reportWorld journal of gastroenterology2013
Low-dose amitriptyline combined with proton pump inhibitor for functional chest pain.
Trial report in World journal of gastroenterology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Efficacy of gut-brain neuromodulators in functional esophageal disorders: a systematic review.BMC gastroenterology · 2026Pooled it
- The Need for Objective Testing in Proton Pump Inhibitor-refractory Extraesophageal Gastroesophageal Reflux Disease.Journal of neurogastroenterology and motility · 2025Article
- Amitriptyline for the Treatment of Extra-esophageal Symptoms in Proton Pump Inhibitor-refractory Patients With Suspected Gastroesophageal Reflux Disease.Journal of neurogastroenterology and motility · 2025Article
- [Drug Therapy for Gastroesophageal Reflux Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025Review
- Low-dose amitriptyline: A potential therapeutic option for chronic pain in older people.British journal of clinical pharmacology · 2025Article
- Current Approach to Dysphagia: A Review Focusing on Esophageal Motility Disorders and Their Treatment.GE Portuguese journal of gastroenterology · 2023Review
- Esophageal Motility Disorders: Current Approach to Diagnostics and Therapeutics.Gastroenterology · 2022Review
- Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial.Frontiers in medicine · 2022Article
- Reflux Hypersensitivity: How to Approach Diagnosis and Management.Current gastroenterology reports · 2020Review
- Diagnosis and Management of Functional Chest Pain in the Rome IV Era.Journal of neurogastroenterology and motility · 2019Review
- Gastroesophageal Reflux Disease Associated With Anxiety: Efficacy and Safety of Fixed Dose Combination of Amitriptyline and Pantoprazole.Gastroenterology research · 2017Article
- Treatment of esophageal motility disorders based on the chicago classification.Current treatment options in gastroenterology · 2014Article
- Review
- New therapies for non-cardiac chest pain.Current gastroenterology reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the efficacy of amitriptyline with proton pump inhibitor (PPI) for the treatment of functional chest pain (FCP).
methodsThis was a randomized, open-label trial investigating the addition of low dose amitriptyline (10 mg at bedtime) to a conventional dose of rabeprazole (20 mg/d) (group A, n = 20) vs a double-dose of rabeprazole (20 mg twice daily) (group B, n = 20) for patients with FCP whose symptoms were refractory to PPI. The primary efficacy endpoints were assessed by global symptom score assessment and the total number of individuals with > 50% improvement in their symptom score.
resultsThe between-group difference in global symptom scores was statistically significant during the last week of treatment (overall mean difference; 3.75 ± 0.31 vs 4.35 ± 0.29, the between-group difference; P < 0.001). Furthermore, 70.6% of patients in group A had their symptoms improve by > 50%, whereas only 26.3% of patients in group B had a similar treatment response (70.6% vs 26.3%, P = 0.008). Specifically, patients in group A had a significantly greater improvement in the domains of body pain and general health perception than did patients in group B (52.37 ± 17.00 vs 41.32 ± 12.34, P = 0.031 and 47.95 ± 18.58 vs 31.84 ± 16.84, P = 0.01, respectively).
conclusionAdding amitriptyline to a PPI was more effective than a double-dose of PPI in patients with FCP refractory to a conventional dose of PPI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.